Abstract
AIM: This study aimed to assess the impact of GSTP1, GSTM1, and GSTT1 polymorphisms on the response to oxaliplatin-based chemotherapy and survival outcomes in gastric cancer patients from Northwest China. PATIENTS AND METHODS: Genotypes of GSTP1, GSTM1, and GSTT1 were analyzed in 185 gastric cancer patients receiving SOX/XELOX regimens. The associations of these genotypes with the objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were evaluated through logistic regression and Kaplan-Meier/Cox model analyses. RESULTS: Patients carrying the GSTP1(AG+GG) genotype exhibited a significantly better chemotherapy response (OR = 0.301, p = 0.022) compared to those with the AA genotype. Additionally, the GSTP1 (AG+GG) genotype conferred a reduced risk of disease progression (HR = 1.645, log-rank p = 0.003) and mortality (HR = 1.705, log-rank p = 0.007) relative to the AA genotype. No significant associations were observed for GSTM1 or GSTT1 individually. However, the combined GSTP1(AG+GG)/GSTM1- genotype was linked to an improved chemotherapy response and significantly better overall and progression-free survival. CONCLUSION: The GSTP1 genotype status could be a valuable predictive biomarker for treatment response and survival, potentially facilitating more personalized therapeutic approaches for gastric cancer.